London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

GSK has had another setback in its oncology business ... means it can only be used as second-line maintenance therapy after platinum-based chemotherapy in patients with these cancers whose ...

GSK “believes these patents provided the foundational technology used in both Moderna’s COVID-19 and RSV mRNA-based vaccines,” the spokesperson said. “We are willing to license these ...

Luxury fashion and lifestyle group Kering, pharma giant GSK and building materials producer Holcim have become the first businesses to set verified science-based targets for nature. The Science-Based ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

UK-based GSK (LSE: GSK) has announced new data from its Phase III trial of Arexvy (RSV vaccine), presented at the 2024 CHEST annual meeting. The trial, which examined the vaccine’s safety and efficacy ...

Teva Pharmaceutical Industries Ltd. ADR-0.81% $21.06B ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

Science Based Targets Network announces first cohort of companies to secure validation for goals that aim to reduce corporate impacts on freshwater and land Pharmaceuticals giant GSK, cement ...